Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hepatitis, Viral, Human

ClinicalTrials.gov lists 4,050 trials for Hepatitis, Viral, Human or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 187.

MeSH D006525 Infections C01 C06
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 473 Phase 1/2 Phase 1/2 100 Phase 2 Phase 2 642 Phase 2/3 Phase 2/3 64 Phase 3 Phase 3 614 Phase 4 Phase 4 653 Not applicable Not applicable 492 Observational Observational 1,002 Phase 1 Phase 1 473 Phase 1/2 Phase 1/2 100 Phase 2 Phase 2 642 Phase 2/3 Phase 2/3 64 Phase 3 Phase 3 614 Phase 4 Phase 4 653 Not applicable Not applicable 492 Observational Observational 1,002

Trials per phase

1 more section with rows

43 of the 4,050 trials are tagged with Hepatitis, Viral, Human itself; the rest are tagged with a narrower condition beneath it.

Get the Hepatitis, Viral, Human report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hepatitis, Viral, Human trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 242

1990: 1 trials (Observational 1) 1991: 1 trials (Observational 1) 1992: 4 trials (Observational 2, Phase 2 1, Phase 1 1) 1993: 4 trials (Observational 1, Phase 3 2, Phase 2 1) 1994: 2 trials (Observational 1, Phase 3 1) 1995: 4 trials (Phase 4 1, Phase 3 2, Phase 2 1) 1996: 1 trials (Phase 4 1) 1997: 9 trials (Observational 2, Phase 3 4, Phase 2/3 1, Phase 2 2) 1998: 8 trials (Observational 2, Phase 3 1, Phase 2/3 1, Phase 2 4) 1999: 15 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 6, Phase 2 1, Phase 1/2 1) 2000: 22 trials (Observational 5, Not applicable 1, Phase 4 2, Phase 3 10, Phase 2 4) 2001: 36 trials (Observational 9, Not applicable 1, Phase 4 2, Phase 3 6, Phase 2 13, Phase 1/2 2, Phase 1 3) 2002: 60 trials (Observational 6, Not applicable 1, Phase 4 13, Phase 3 22, Phase 2/3 3, Phase 2 15) 2003: 85 trials (Other 1, Observational 9, Not applicable 6, Phase 4 23, Phase 3 26, Phase 2 12, Phase 1/2 6, Phase 1 2) 2004: 104 trials (Observational 20, Not applicable 6, Phase 4 24, Phase 3 28, Phase 2/3 1, Phase 2 18, Phase 1/2 4, Phase 1 3) 2005: 149 trials (Observational 37, Not applicable 12, Phase 4 35, Phase 3 27, Phase 2/3 1, Phase 2 27, Phase 1/2 3, Phase 1 7) 2006: 151 trials (Observational 24, Not applicable 11, Phase 4 29, Phase 3 43, Phase 2/3 4, Phase 2 25, Phase 1/2 3, Phase 1 12) 2007: 158 trials (Observational 24, Not applicable 13, Phase 4 40, Phase 3 28, Phase 2/3 3, Phase 2 28, Phase 1/2 4, Phase 1 18) 2008: 169 trials (Observational 32, Not applicable 16, Phase 4 37, Phase 3 29, Phase 2 25, Phase 1/2 7, Phase 1 23) 2009: 188 trials (Observational 38, Not applicable 16, Phase 4 31, Phase 3 10, Phase 2/3 2, Phase 2 40, Phase 1/2 8, Phase 1 43) 2010: 184 trials (Observational 43, Not applicable 6, Phase 4 26, Phase 3 24, Phase 2/3 3, Phase 2 44, Phase 1/2 2, Phase 1 36) 2011: 242 trials (Observational 55, Not applicable 19, Phase 4 35, Phase 3 47, Phase 2/3 2, Phase 2 40, Phase 1/2 8, Phase 1 36) 2012: 232 trials (Observational 56, Not applicable 15, Phase 4 22, Phase 3 58, Phase 2/3 2, Phase 2 35, Phase 1/2 7, Phase 1 37) 2013: 199 trials (Observational 37, Not applicable 17, Phase 4 35, Phase 3 37, Phase 2/3 6, Phase 2 37, Phase 1/2 7, Phase 1 23) 2014: 206 trials (Observational 45, Not applicable 24, Phase 4 27, Phase 3 44, Phase 2/3 5, Phase 2 26, Phase 1/2 4, Phase 1 31) 2015: 242 trials (Observational 59, Not applicable 23, Phase 4 51, Phase 3 40, Phase 2/3 6, Phase 2 38, Phase 1/2 4, Phase 1 21) 2016: 209 trials (Observational 60, Not applicable 30, Phase 4 37, Phase 3 34, Phase 2/3 4, Phase 2 28, Phase 1/2 1, Phase 1 15) 2017: 195 trials (Observational 56, Not applicable 28, Phase 4 43, Phase 3 26, Phase 2/3 2, Phase 2 18, Phase 1/2 3, Phase 1 19) 2018: 178 trials (Observational 56, Not applicable 31, Phase 4 36, Phase 3 9, Phase 2/3 4, Phase 2 20, Phase 1/2 4, Phase 1 18) 2019: 183 trials (Observational 53, Not applicable 48, Phase 4 25, Phase 3 9, Phase 2/3 4, Phase 2 25, Phase 1/2 2, Phase 1 17) 2020: 131 trials (Observational 34, Not applicable 33, Phase 4 16, Phase 3 5, Phase 2 20, Phase 1/2 3, Phase 1 20) 2021: 108 trials (Observational 33, Not applicable 22, Phase 4 13, Phase 3 5, Phase 2/3 1, Phase 2 16, Phase 1/2 2, Phase 1 16) 2022: 123 trials (Observational 41, Not applicable 27, Phase 4 15, Phase 3 4, Phase 2 17, Phase 1/2 2, Phase 1 17) 2023: 111 trials (Observational 44, Not applicable 21, Phase 4 7, Phase 3 1, Phase 2/3 2, Phase 2 16, Phase 1/2 4, Phase 1 16) 2024: 111 trials (Observational 42, Not applicable 22, Phase 4 8, Phase 3 2, Phase 2 16, Phase 1/2 3, Phase 1 18) 2025: 93 trials (Observational 34, Not applicable 15, Phase 4 6, Phase 3 12, Phase 2/3 3, Phase 2 13, Phase 1/2 3, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 73
2025 93
2024 111
2023 111
2022 123
2021 108
2020 131
2019 183
2018 178
2017 195

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 90 trials starting in 2026 and about 95 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 149 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 2,795 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hepatitis, Viral, Human trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 473
Phase 1/2 100
Phase 2 642
Phase 2/3 64
Phase 3 614
Phase 4 653
Not applicable 492
Observational 1,002
Expanded access 10

How many Hepatitis, Viral, Human trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 95
Recruiting 170
Enrolling by invitation 13
Active, not recruiting 87
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hepatitis, Viral, Human trials? (12)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 187
Merck Sharp & Dohme LLC 184
Gilead Sciences 165
Hoffmann-La Roche 139
Bristol-Myers Squibb 125

Showing 5 of 12 sponsors.

Start your 14-day trial Email me all 12 sponsors as a PDF

Which drugs are being tested for Hepatitis, Viral, Human? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEGinterferon alfa-2a 247
Entecavir 153
Peginterferon Alfa-2B 110
GS-7340 75
Daclatasvir 73

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ribavirine 553
tenofovir disproxil fumarate 118
Sofosbuvir, Sovaldi 109
Engerix™ 67
Telaprevir 54

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hepatitis, Viral, Human trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Anaemia 650 132
Pneumonia 578 184
Gastroenteritis 286 100
Pyrexia 233 96
Death 219 41

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hepatitis, Viral, Human? (113)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Global burden of liver disease: 2023 update. Journal of hepatology 2023 Yes
Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis. PloS one 2022 Yes
Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan-the Formosa-Like Group. Journal of viral hepatitis 2021 Yes
Current situation of viral hepatitis in Egypt. Microbiology and immunology 2021 Yes
Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches. Cells 2021 Yes

Showing 5 of 113 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages